Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.61−0.20 (-3.44%)
Close on Nov 17, 2026Market cap $287.64MP/E –Yield –
Emergent BioSolutions operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Emergent BioSolutions's operating income for the twelve months ending Sep 30, 2026 was -$179.80M, down 251.7% year over year. For fiscal 2025 it was $100.10M. Over ten years it grew -3.4% a year on average. The highest annual figure on record is $438.50M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.10M | – |
| FY2024 | Dec 31, 2024 | -$108.70M | – |
| FY2023 | Dec 31, 2023 | -$726.40M | – |
| FY2022 | Dec 31, 2022 | -$170.00M | -149.8% |
| FY2021 | Dec 31, 2021 | $341.40M | -22.1% |
| FY2020 | Dec 31, 2020 | $438.50M | +284.3% |
| FY2019 | Dec 31, 2019 | $114.10M | +27.1% |
| FY2018 | Dec 31, 2018 | $89.80M | -27.8% |
| FY2017 | Dec 31, 2017 | $124.30M | +17.8% |
| FY2016 | Dec 31, 2016 | $105.50M | -25.4% |
| FY2015 | Dec 31, 2015 | $141.51M | +58.7% |
| FY2014 | Dec 31, 2014 | $89.19M | +108.4% |
| FY2013 | Dec 31, 2013 | $42.80M | +42.8% |
| FY2012 | Dec 31, 2012 | $29.97M | -6.6% |
| FY2011 | Dec 31, 2011 | $32.10M | -56.4% |
| FY2010 | Dec 31, 2010 | $73.56M | +83.2% |
| FY2009 | Dec 31, 2009 | $40.15M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$37.30M | -148.8% |
| Q2 FY2026 | Jun 30, 2026 | -$125.10M | -7918.8% |
| Q1 FY2026 | Mar 31, 2026 | $10.50M | -79.0% |
| Q4 FY2025 | Dec 31, 2025 | -$27.90M | – |
| Q3 FY2025 | Sep 30, 2025 | $76.50M | +18.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.60M | – |
| Q1 FY2025 | Mar 31, 2025 | $49.90M | +25.4% |
| Q4 FY2024 | Dec 31, 2024 | -$9.50M | – |
| Q3 FY2024 | Sep 30, 2024 | $64.50M | – |
| Q2 FY2024 | Jun 30, 2024 | -$203.50M | – |
| Q1 FY2024 | Mar 31, 2024 | $39.80M | – |
| Q4 FY2023 | Dec 31, 2023 | -$43.80M | – |
| Q3 FY2023 | Sep 30, 2023 | -$242.10M | – |
| Q2 FY2023 | Jun 30, 2023 | -$292.90M | – |
| Q1 FY2023 | Mar 31, 2023 | -$147.60M | -2239.1% |
| Q4 FY2022 | Dec 31, 2022 | -$55.30M | -119.3% |
| Q3 FY2022 | Sep 30, 2022 | -$45.30M | – |
| Q2 FY2022 | Jun 30, 2022 | -$76.30M | -1174.6% |
| Q1 FY2022 | Mar 31, 2022 | $6.90M | -92.5% |
| Q4 FY2021 | Dec 31, 2021 | $286.80M | +11.1% |
| Q3 FY2021 | Sep 30, 2021 | -$44.70M | -172.9% |
| Q2 FY2021 | Jun 30, 2021 | $7.10M | -94.4% |
| Q1 FY2021 | Mar 31, 2021 | $92.20M | – |
| Q4 FY2020 | Dec 31, 2020 | $258.10M | +231.7% |
| Q3 FY2020 | Sep 30, 2020 | $61.30M | -13.3% |
| Q2 FY2020 | Jun 30, 2020 | $126.00M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.60M | – |
| Q4 FY2019 | Dec 31, 2019 | $77.80M | +594.6% |
| Q3 FY2019 | Sep 30, 2019 | $70.70M | +231.9% |
| Q2 FY2019 | Jun 30, 2019 | -$7.00M | -110.5% |
| Q1 FY2019 | Mar 31, 2019 | -$27.40M | – |
| Q4 FY2018 | Dec 31, 2018 | $11.20M | -78.9% |
| Q3 FY2018 | Sep 30, 2018 | $21.30M | -55.4% |
| Q2 FY2018 | Jun 30, 2018 | $66.80M | +683.2% |
| Q1 FY2018 | Mar 31, 2018 | -$9.50M | -163.7% |
| Q4 FY2017 | Dec 31, 2017 | $53.09M | +4.3% |
| Q3 FY2017 | Sep 30, 2017 | $47.77M | – |
| Q2 FY2017 | Jun 30, 2017 | $8.53M | – |
| Q1 FY2017 | Mar 31, 2017 | $14.91M | – |
| Q4 FY2016 | Dec 31, 2016 | $50.91M | – |
See a number that looks wrong?